Crispr Therapeutics AG (NASDAQ:CRSP) rose 8.6% during mid-day trading on Thursday . The company traded as high as $36.29 and last traded at $35.59. Approximately 714,464 shares traded hands during trading, a decline of 41% from the average daily volume of 1,212,102 shares. The stock had previously closed at $32.77.
CRSP has been the subject of a number of research analyst reports. Zacks Investment Research lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Chardan Capital restated a “buy” rating and set a $72.50 price objective on shares of Crispr Therapeutics in a report on Wednesday, August 8th. Citigroup reduced their price objective on Crispr Therapeutics from $51.00 to $50.00 and set a “neutral” rating on the stock in a report on Friday, August 24th. Finally, Cann restated a “hold” rating on shares of Crispr Therapeutics in a report on Monday, September 17th. One analyst has rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Crispr Therapeutics currently has an average rating of “Buy” and a consensus price target of $62.47.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.19). Crispr Therapeutics had a negative net margin of 245.57% and a negative return on equity of 39.58%. The company had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $1.47 million. Equities research analysts forecast that Crispr Therapeutics AG will post -2.92 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in CRSP. Federated Investors Inc. PA purchased a new position in shares of Crispr Therapeutics in the 2nd quarter valued at $37,101,000. ARK Investment Management LLC increased its holdings in shares of Crispr Therapeutics by 544.0% in the 2nd quarter. ARK Investment Management LLC now owns 467,140 shares of the company’s stock valued at $27,449,000 after acquiring an additional 394,606 shares during the period. Orbimed Advisors LLC increased its holdings in shares of Crispr Therapeutics by 375.3% in the 2nd quarter. Orbimed Advisors LLC now owns 496,200 shares of the company’s stock valued at $29,157,000 after acquiring an additional 391,799 shares during the period. Global Thematic Partners LLC increased its holdings in shares of Crispr Therapeutics by 87.7% in the 3rd quarter. Global Thematic Partners LLC now owns 497,276 shares of the company’s stock valued at $22,054,000 after acquiring an additional 232,362 shares during the period. Finally, FMR LLC purchased a new position in shares of Crispr Therapeutics in the 2nd quarter valued at $11,629,000. Institutional investors and hedge funds own 39.03% of the company’s stock.
Crispr Therapeutics Company Profile (NASDAQ:CRSP)
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.